33 research outputs found

    Virtual Compton Scattering and Neutral Pion Electroproduction in the Resonance Region up to the Deep Inelastic Region at Backward Angles

    Full text link
    We have made the first measurements of the virtual Compton scattering (VCS) process via the H(e,e′p)γ(e,e'p)\gamma exclusive reaction in the nucleon resonance region, at backward angles. Results are presented for the WW-dependence at fixed Q2=1Q^2=1 GeV2^2, and for the Q2Q^2-dependence at fixed WW near 1.5 GeV. The VCS data show resonant structures in the first and second resonance regions. The observed Q2Q^2-dependence is smooth. The measured ratio of H(e,e′p)γ(e,e'p)\gamma to H(e,e′p)π0(e,e'p)\pi^0 cross sections emphasizes the different sensitivity of these two reactions to the various nucleon resonances. Finally, when compared to Real Compton Scattering (RCS) at high energy and large angles, our VCS data at the highest WW (1.8-1.9 GeV) show a striking Q2Q^2- independence, which may suggest a transition to a perturbative scattering mechanism at the quark level.Comment: 20 pages, 8 figures. To appear in Phys.Rev.

    Dynamics of the 16^{16}O(e,e'p) cross section at high missing energies

    Get PDF
    We measured the cross section and response functions (R_L, R_T, and R_LT) for the 16O(e,e'p) reaction in quasielastic kinematics for missing energies 25 60 MeV and P_miss > 200 MeV/c, the cross section is relatively constant. Calculations which include contributions from pion exchange currents, isobar currents and short-range correlations account for the shape and the transversity but only for half of the magnitude of the measured cross section

    Cardiovascular disease and diabetes in people with severe mental illness

    No full text
    Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed to an increased risk of the modifiable coronary heart disease risk factors, obesity, smoking, diabetes, hypertension, and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain and further increase the risk of adverse metabolic effects which may result in further increased incidence of cardiovascular disease. Patients have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement aiming to improve the care of patients suffering from severe mental illness. The intention is to initiate co-operation and shared care between the different health care professionals and to increase the awareness of psychiatrists caring for patients suffering from severe mental illness to screen and treat increased cardiovascular risk factors and diabetes.status: publishe

    Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

    Get PDF
    AbstractPeople with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed in part to an increased risk of the modifiable coronary heart disease risk factors; obesity, smoking, diabetes, hypertension and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and treat cardiovascular risk factors and diabetes

    Maladie cardiovasculaire et diabete chez les sujets souffrant d'une maladie mentale severe. Declaration de position de l'European Psychiatric Association (EPA), soutenue par l'European Association for the Study of Diabetes (EASD) et l'European Society of Cardiology

    No full text
    Les personnes souffrant de maladies mentales sévères telles que la schizophrénie, la dépression ou le trouble bipolaire sont en moins bonne santé physique et ont une espérance de vie moindre que la population générale. La surmortalité cardiovasculaire associée à la schizophrénie et au trouble bipolaire est en partie attribuée à une majoration des facteurs de risque coronarien modifiables : obésité, tabagisme, diabète, hypertension et dyslipidémie. Les antipsychotiques et peut-être d’autres psychotropes, les antidépresseurs par exemple, peuvent induire une prise de poids ou aggraver d’autres facteurs métaboliques de risque cardiovasculaire. Les patients peuvent avoir un accès restreint à la médecine générale, avec des opportunités de dépistage et de prévention du risque cardiovasculaire inférieures à celles que l’on attendrait dans une population non psychiatrique. L’European Psychiatric Association (EPA), soutenue par l’European Association for the Study of Diabetes (EASD) et l’European Society of Cardiology (ESC), a publié cette déclaration de position dans le but d’améliorer la prise en charge des patients souffrant de maladies mentales sévères. L’intention est d’amorcer une coopération et une prise en charge partagée entre les différents professionnels de la santé et de sensibiliser les psychiatres et les médecins de première ligne qui s’occupent de patients souffrant de maladies mentales sévères au dépistage et au traitement des facteurs de risque cardiovasculaire et du diabète

    Supplementary Material for: The New Hamburg-Hannover Agitation Scale in Clinical Samples: Manifestation and Differences of Agitation in Depression, Anxiety, and Borderline Personality Disorder

    No full text
    <p><b><i>Background/Aims:</i></b> Agitation is a burdening phenomenon that occurs in a variety of psychiatric disorders. The aim of this study was to give a first direction for agitation occurrence in depression, anxiety disorder, and borderline personality disorder (BPD) as well as in healthy controls with and without psychiatric record. <b><i>Methods:</i></b> Using the Hamburg-Hannover Agitation Scale (H<sub>2</sub>A), an instrument that allows for the measurement of agitation independently of the presence of a specific disorder, a patient sample (<i>n</i> = 158) and a healthy control group (<i>n</i> = 685) with (<i>n</i> = 94) and without (<i>n</i> = 591) psychiatric record were examined. The data were mainly analysed using ANOVAs and post hoc tests. <b><i>Results:</i></b> Patients showed significantly higher H<sub>2</sub>A agitation levels than healthy controls. Within the clinical sample, BPD patients exhibited the strongest manifestation of agitation, scoring significantly higher than the depression and the anxiety disorder sample, while these two subgroups did not significantly differ from each other. Moreover, healthy subjects with a psychiatric record experienced a significantly stronger agitation than subjects without a psychiatric record. <b><i>Conclusion:</i></b> Further studies are needed with larger, more balanced, and differentiated sample sizes including a wider range of clinical pictures. The results demonstrate that agitation occurs and differs in psychiatric patients as well as in healthy controls.</p

    Dimensionsstabile Elektroden fuer die Schmelzflusselektrolyse (Ersatz von Petrolkoks)

    No full text
    With 46 refs., 20 tabs. and 47 figs.SIGLECopy held by FIZ Karlsruhe; available from UB/TIB Hannover / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekDEGerman
    corecore